Symptomatic Overlap Between Irritable Bowel Syndrome and Microscopic Colitis: A Prospective Study

Abboud, Rami; Pardi, Darrell S.; Kammer, Patricia P.; Loftus, Edward V.

doi:10.1016/s0016-5085(11)61163-3

Cited by 16 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were four studies reporting the prevalence of IBS symptoms in patients with MC, 41,44,48,49 two of which were case series, 44,48 one a case-control study, 49 and one a cross sectional survey. 41 There were three cross-sectional surveys reporting the prevalence of MC in patients with IBS, 14,41,42 one of which also reported the prevalence of IBS in patients with MC and was included in the aforementioned analysis.…”

Section: Resultsmentioning

confidence: 99%

“…41,44,48,49 Detailed characteristics of these studies are provided in Table 1. To define IBS, three studies used the Rome II criteria, 44,48,49 and one used the Rome III criteria.…”

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

“…41,44,48,49 Detailed characteristics of these studies are provided in Table 1. To define IBS, three studies used the Rome II criteria, 44,48,49 and one used the Rome III criteria. 41 There were a total of 420 individuals with histologically confirmed MC recruited into these studies, and the pooled prevalence of IBS in all four studies was 33.4% (95% CI 17.2% to 52.0%), but with significant heterogeneity between studies (I 2 =93.6%, P < 0.001).…”

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

“…41 We contacted authors of another two studies in order to try to obtain these data, but unfortunately these were not available. 48,49 Two of the four studies also reported the prevalence of IBS among other patients with diarrhea in whom random colonic biopsies were normal. 41,49 These studies included a total of 218 patients with MC, of whom 85 (39.0%) had IBS, compared with 129 (20.3%) of 636 patients without MC.…”

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

See 3 more Smart Citations

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis

Kamp

Kane

Ford

2016

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…41,44,48,49 Detailed characteristics of these studies are provided in Table 1. To define IBS, three studies used the Rome II criteria, 44,48,49 and one used the Rome III criteria.…”

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

Section: Prevalence Of Ibs Symptoms In Patients With MCmentioning

confidence: 99%

See 2 more Smart Citations

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis

Kamp

Kane

Ford

2016

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…[6][7][8] Celiac disease is a chronic immune-mediated enteropathy, characterised by T cell sensitisation to gluten in genetically predisposed individuals. The prevalence of a positive serological test for celiac disease in the US and European community is estimated to be between 0.8% and 1.0%.…”

Section: Abbreviationsmentioning

confidence: 99%

Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?

Ford

2015

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Effects of propolis supplementation on irritable bowel syndrome with constipation (IBS‐C) and mixed (IBS‐M) stool pattern: A randomized, double‐blind clinical trial

Miryan

Soleimani

Alavinejad

et al. 2022

Food Science & Nutrition

View full text Add to dashboard Cite

Background Recent evidence indicates that propolis can modulate gastrointestinal (GI) function. This trial aims to assess the efficacy of propolis supplementation on the severity of irritable bowel syndrome (IBS) symptoms. Methods This clinical trial was conducted on 56 subjects with IBS diagnosed by Rome IV criteria. Eligible subjects were randomly assigned to receive either 900 mg/day of propolis or matching placebo tablets for 6 weeks. The IBS symptom severity scale (IBS‐SSS) was used to evaluate IBS severity in five clinically applicable items. Results After adjusting anxiety scores, a significant reduction was observed in the overall score of IBS symptoms (−98.27 ± 105.44), the severity of abdominal pain (−24.75 ± 28.66), and the frequency of abdominal pain (−2.24 ± 3.51) with propolis treatment as compared to placebo (p‐value < .05). Patients in the propolis group were 6.22 times more likely to experience improvement in IBS symptoms than those in the placebo group (95% CI: 1.14–33.9; p‐value: .035). There was no significant change in anthropometric measurements and dietary intakes in both groups (p‐value > .05). Conclusions Our results showed that propolis supplementation might have a beneficial effect on constipation subtype of IBS (IBS‐C) and mixed subtype of IBS (IBS‐M) severity by reducing the severity and frequency of abdominal pain in patients with irritable bowel syndrome (IBS).

show abstract

Symptomatic Overlap Between Irritable Bowel Syndrome and Microscopic Colitis: A Prospective Study

Cited by 16 publications

References 0 publications

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis

Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?

Effects of propolis supplementation on irritable bowel syndrome with constipation (IBS‐C) and mixed (IBS‐M) stool pattern: A randomized, double‐blind clinical trial

Contact Info

Product

Resources

About